Boya Bio: to transfer 100% equity of Nanjing Xinpai Pharmaceutical for a total of 235 million yuan.

Boya Biology Announcement: The company and its wholly-owned subsidiary, Jiangxi Boya Pharmaceutical Investment Co., Ltd., have signed a "Equity Transfer Agreement of Nanjing Xinbai Pharmaceuticals Co., Ltd." with CR Double-Crane. They will transfer 100% of the equity of Nanjing Xinbai Pharmaceuticals Co., Ltd. to CR Double-Crane for a total of 235 million yuan. This transaction constitutes a related party transaction, and related directors have abstained from voting.